Shamburg News · 8-K filed Oct 29, 2026, 4:14 PM EDT
Rezolute Releases Corporate Investor Presentation on Ersodetug Development Programs
RZLT · Rezolute, Inc.
- Reg FD disclosure
- Other event
- Materiality: low
Rezolute, Inc. released an investor presentation on its website on October 29, 2026, furnished as Exhibit 99.1 to this Form 8-K under Regulation FD. The presentation describes the ersodetug development programs for congenital and tumor hyperinsulinism, cash of $108 million with runway through Q1 2028, and an interim upLIFT update reporting 7 of the initial 8 participants met the primary endpoint. The information is furnished and not deemed filed under Section 18 of the Exchange Act.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001104659-26-120205.
Written from the filing by Shamburg Markets. Figures are as reported by the company.